We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In what could see another use added to Merck & Co.’s immuno-oncology star Keytruda, the checkpoint inhibitor is set for testing in glioblastoma as part of a combo with Agenus’ cancer vaccine Prophage.